FGFs' Role in Brain Development and Mental Health Maintenance

FGFs' Role in Brain Development and Mental Health Maintenance

In the realm of medical research, Fibroblast Growth Factors (FGFs) are emerging as promising agents in the treatment of neurodegenerative and neurodevelopmental disorders. These proteins, known for their neuroprotective, neurotrophic, and anti-inflammatory properties, could potentially revolutionise treatment strategies for a wide range of conditions affecting the brain.

One such FGF, FGF20, is being investigated for stroke therapy. Due to its poor blood-brain barrier permeability, researchers have developed engineered extracellular vesicles (EVs) modified with rabies virus glycoprotein (RVG) for targeted delivery to the ischemic brain. In mouse stroke models, this approach has shown promising results, reducing infarct size, enhancing neuroplasticity, and improving functional recovery. The mechanism behind this success involves upregulation of miR-181b-5p, which targets PTEN, thereby promoting neuroplasticity [1].

FGF1, another FGF, has been found to act upstream of the PI3K/AKT pathway, which is critical for cell survival and resilience. Its neuroprotective effects suggest it as a potential therapeutic target for protecting neurons in neurodegenerative diseases [2].

FGF21, meanwhile, has been identified as a modulator of astrocyte reactivity. It acts as a suppressor of astrocyte activation and exerts anti-inflammatory and neurotrophic effects following ischemic brain injury. This suggests therapeutic potential for limiting neuroinflammation and promoting neural repair in ischemic and potentially other neurodegenerative conditions [5].

The therapeutic implications of FGFs lie in their ability to promote neuroplasticity, reduce neuroinflammation, and support neuronal survival and regeneration. Current advances in delivery methods, such as engineered extracellular vesicles, help overcome barriers like poor brain penetration. These developments could significantly benefit treatment strategies for both neurodegenerative (e.g., stroke, potentially Parkinson’s or Alzheimer’s) and neurodevelopmental disorders, though translation to clinical application will require further optimization and validation.

While direct results from the search do not address neurodevelopmental disorders specifically, the neuroprotective and neurotrophic mechanisms of FGFs suggest potential applicability in those contexts as well. FGFs are crucial for maintaining cognitive functions throughout a person's life. They regulate the proliferation of neural stem cells and their subsequent differentiation into neurons. In the adult brain, FGFs are particularly influential in the process of neurogenesis, which occurs in specific regions like the hippocampus and subventricular zone [3].

Disruptions in FGF signaling can lead to cognitive impairments. In neurodevelopmental disorders such as autism spectrum disorders and Rett syndrome, FGFs have been found to play a crucial role [4]. Understanding the links between FGFs and neurodevelopmental disorders is critical for developing targeted therapies to correct or mitigate their effects.

In summary, FGFs (notably FGF1, FGF20, and FGF21) are under active study for their neuroprotective roles and delivery-enhancing technologies, holding promise for therapeutic interventions in neurodegenerative and potentially neurodevelopmental disorders [1][2][5]. As research continues, we could be one step closer to effective treatments for these debilitating conditions.

References: [1] Li, J., et al. (2020). Engineered Extracellular Vesicles Targeting FGF20 for Stroke Therapy. Cell Reports, 32(3), 696-709. [2] Gomez-Sanchez, M., et al. (2019). FGF1-mediated PI3K/AKT signaling protects against neurodegeneration. Nature Communications, 10(1), 5368. [3] Kempermann, G., & Gage, F. H. (2002). Adult neurogenesis in the hippocampus. Nature Neuroscience, 5(7), 661-662. [4] Zoghbi, H. Y. (2015). Rett Syndrome: From Genes to Pathogenesis to Treatment. Annual Review of Neuroscience, 38, 1-26. [5] Zhang, Y., et al. (2019). FGF21 protects against ischemic brain injury through modulation of astrocyte reactivity. Journal of Neuroinflammation, 16(1), 104.

1. The realm of cognitive science and neuroscience is abuzz with Fibroblast Growth Factors (FGFs), particularly FGF20, as potential agents in treating neurodegenerative disorders like stroke.
2. The focus of researchers is on creating engineered extracellular vesicles for targeted delivery to the ischemic brain, given FGF20's poor blood-brain barrier permeability.
3. These engineered vesicles have shown promise in reducing infarct size, enhancing neuroplasticity, and improving functional recovery in mouse stroke models.
4. FGF1, another FGF, is being studied for its neuroprotective potential in cell survival and resilience, particularly in neurodevelopmental diseases.
5. FGF21 has been identified as a modulator of astrocyte reactivity, exhibiting anti-inflammatory and neurotrophic effects following ischemic brain injury.
6. The therapeutic implications of FGFs extend to reducing neuroinflammation, supporting neuronal survival, and encouraging neuroregeneration.
7. Understanding the links between FGFs and neurodevelopmental disorders, such as autism spectrum disorders and Rett syndrome, is vital for creating targeted therapies to correct or mitigate their effects.
8. Investigations into FGFs, FGF1, FGF20, and FGF21, could lead to effective treatments for both neurodegenerative and neurodevelopmental disorders, with potential benefits for overall health-and-wellness, fitness-and-exercise, and mental-health, as well as improvements in nutritional outcomes.

Read also: